Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma
Abstract
:1. Introduction
2. Autologous Stem-Cell Transplantation
3. Allogeneic Stem-Cell Transplantation (allo-HCT)
4. Haploidentical Stem-Cell Transplantation
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Eichenauer, D.A.; Aleman, B.M.P.; Andre, M.; Federico, M.; Hutchings, M.; Illidge, T.; Engert, A.; Ladetto, M. Hodgkin lymphoma: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow up. Ann. Oncol. 2018, 29 (Suppl. 4), iv19–iv29. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistic. Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Shanbhag, S.; Ambinder, R. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J. Clin. 2018, 68, 116–132. [Google Scholar] [CrossRef] [PubMed]
- Alexander, F.E.; Jarrett, R.F.; Lawrence, D.; Armstrong, A.A.; Freeland, J.; Gokhale, D.A.; Kane, E.; Taylor, G.M.; Wright, D.H.; Cartwright, R.A. Risk factors for Hodgkin’s disease by Epstein-Barr virus (EBV) ststus: Prior infection by EBV and other agents. Br. J. Cancer 2000, 82, 1117–1121. [Google Scholar] [CrossRef] [Green Version]
- Ekstrand, B.C.; Horning, S.J. Hodgkin’s disease. Blood Rev. 2002, 16, 111–117. [Google Scholar] [CrossRef]
- Diehl, V.; Stein, H.; Hummel, M.; Zollinger, R.; Connors, J.M. Hodgkin’s lymphoma: Biology and treatment strategies for primary, refractory and relapsed disease. Hematology 2003, 2003, 225–247. [Google Scholar] [CrossRef] [Green Version]
- Hasenclever, D.; Diehl, V.; Armitage, J.O.; Assouline, D.; Björkholm, M.; Brusamolino, E.; Canellos, G.P.; Carde, P.; Crowther, D.; Cunningham, D. A prognostic scvore for advanced Hodgkin’s diosease. International Prognostic Factors Project on Advanced Hodgkin’s disease. N. Engl. J. Med. 1998, 339, 1506–1514. [Google Scholar] [CrossRef]
- Gallamini, A.; Hutchings, M.; Riggaci, L.; Specht, L.; Merli, F.; Hansen, M.; Patti, C.; Loft, A.; Di Raimondo, F.; D’Amore, F.; et al. Early intertrim 2-[18F]Fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma:a report from a joint Italian-Danish study. J. Clin. Oncol. 2007, 25, 3746–3752. [Google Scholar] [CrossRef] [Green Version]
- Ansell, S.M. Brenduximab vedotin. Blood 2014, 124, 3197–3200. [Google Scholar] [CrossRef]
- Shah, G.; Moskowitz, C.H. Transplant strategies in relapsed/reafractory Hodgkin lymphoma. Blood 2018, 131, 1689–1697. [Google Scholar] [CrossRef]
- Sureda, A.; Barbosa Pereira, M.I.; Dreger, P. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin’s lymphoma. Curr. Opin. Oncol. 2012, 24, 727–732. [Google Scholar] [CrossRef]
- Diehl, V.; Franklin, J.; Pfreundschuh, M.; Lathan, B.; Paulus, U.; Hasenclever, D.; Tesch, H.; Herrmann, R.; Dörken, B.; Müller-Hermelink, H.K.; et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N. Engl. J. Med. 2003, 348, 2386–2395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Linch, D.C.; Winfield, D.; Goldstone, A.H.; Moir, D.; Hancock, B.; McMillan, A.; Chopra, R.; Milligan, D.; Hudson, G.V. Dose intensification with autologous bone-marrow transplantation in relapsed and resist-ant Hodgkin’s disease: Results of a BNLI randomised trial. Lancet 1993, 341, 1050–1054. [Google Scholar] [CrossRef]
- Schmitz, N.; Pfistner, B.; Sextro, M.; Sieber, M.; Carella, A.M.; Haenel, M.; Boissevain, F.; Zschaber, R.; Müller, P.; Kirchner, H.; et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet 2002, 359, 2065–2071. [Google Scholar] [CrossRef]
- Duarte, R.F.; Labopin, M.; Bader, P.; Basak, G.W.; Bonini, C.; Chabannon, C.; Corbacioglu, S.; Dreger, P.; Dufour, C.; Gennery, A.R.; et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2019. Bone Marrow Transpl. 2019, 54, 1525–1552. [Google Scholar] [CrossRef]
- Carreras, E.; Dufour, E.; Mohty, M.; Kroger, N. The EBMT Handbook: Hematopietic Stem Cell Transplantation and Cellular Therapie; Springer: Cham, Switzerland, 2019; pp. 653–662. [Google Scholar]
- Santoro, A.; Mazza, R.; Pulsoni, A.; Re, A.; Bonfichi, M.; Zilioli, V.R.; Salvi, F.; Merli, F.; Anastasia, A.; Luminari, S.; et al. bendamustine in combination woth gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter ophase II study. J. Clin. Oncol. 2016, 34, 3293–3299. [Google Scholar] [CrossRef] [Green Version]
- Moskowitz, A.J.; Yahalom, J.; Kewalramani, T.; Maragulia, J.C.; Vanak, J.M.; Zelenetz, A.D.; Moskowitz, C.H. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010, 116, 4934–4937. [Google Scholar] [CrossRef] [Green Version]
- Josting, A.; Rudolph, C.; Reiser, M.; Mapara, M.; Sieber, M.; Kirchner, H.H.; Dörken, B.; Hossfeld, D.K.; Diehl, V.; Engert, A.; et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann. Oncol. 2002, 13, 1628–1635. [Google Scholar] [CrossRef]
- Bartlett, N.L.; Niedzwiecki, D.; Jonson, J.L.; Friedberg, J.W.; Johnson, K.B.; Van Besien, K.; Zelenetz, A.D.; Cheson, B.D.; Canellos, G.P.; Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann. Oncol. 2007, 18, 1071–1079. [Google Scholar] [CrossRef]
- Moskovitz, A.J.; Schoder, H.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kobos, R.; et al. PET -adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: A non-randomised, oper-label, single center, phase 2 study. Lancet Oncol. 2015, 16, 284–292. [Google Scholar] [CrossRef]
- Chen, R.; Palmer, J.M.; Martin, P.; Tsai, N.; Kim, Y.; Chen, B.T.; Popplewell, L.; Siddiqi, T.; Thomas, S.H.; Mott, M.; et al. Results of a multiventer phase II trial of brentuximab vedotin as second -line therapy before autologous transplantation in relapsed/refractpry Hodgkin lymphoma. Biol. Blood Marrow Transpl. 2015, 21, 2136–2140. [Google Scholar] [CrossRef] [Green Version]
- Garcia-Sanz, R.; Sureda, A.; Gonzales, A.P.; La Cruz, F.; Sanches-Gonzales, B.; Rodriguez, A.; Domingo-Domenech, E.; Miriam, M.; Lopez, J.; Jose, L.P.; et al. Brenduximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: A trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) (abstract). Blood 2016, 128, 1109. [Google Scholar]
- LaCasce, A.S.; Bociek, R.G.; Sawas, A.; Caimi, P.; Agura, E.; Matous, J.; Ansell, S.M.; Crosswell, H.E.; Islas-Ohlmayer, M.; Behler, C.; et al. Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018, 132, 40–48, PMCID:PMC60735. [Google Scholar] [CrossRef] [PubMed]
- Cassaday, R.D.; Fromm, J.; Cowan, A.J.; Libby, E.N.; Phillip, M.; Behnja, S.; Nartea, M.; Press, O.; Gopal, A. Safety and activity of brenduximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (cHL) initial result of a phase I/II trial (abstract). Blood 2016, 128, 1834. [Google Scholar] [CrossRef]
- Hagenbeek, A.; Zijlstra, J.; Lugtenburg, P.; van Imhoff, G.; Nijland, M.; Tonino, S.; Hutchings, M.; Spiering, M.; Liu, R.; Burggraaf, C.N.; et al. Transplant BRaVE: Combining brenduximab-vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: A phase 1 dose-escalation study. Hematologica 2016, 101, 44. [Google Scholar]
- Herrera, A.F.; Moskowitz, A.J.; Bartlett, N.L.; Vose, J.M.; Ramchandren, R.; Feldman, T.A.; LaCasce, A.S.; Ansell, S.M.; Moskowitz, C.H.; Fenton, K.; et al. Interim results from a phase ½ study of brenduximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018, 131, 1183–1194. [Google Scholar] [CrossRef]
- Frederico, M.; Bellei, M.; Brice, P.; Brugiatelli, M.; Nagler, A.; Gisselbrecht, C.; Moretti, L.; Colombat, P.; Luminari, S.; Fabbiano, F.; et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J. Clin. Oncol. 2003, 21, 2320–2325. [Google Scholar] [CrossRef] [PubMed]
- Moskowitz, A.J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; et al. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J. Clin. Oncol. 2021. Epub ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Merryman, R.; Redd, R.; Nishihori, T.; Chavez, J.; Nieto, Y.; Darrah, J.M.; Rao, U.; Byrne, M.T.; Bond, D.A.; Maddocks, K.J.; et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021, 6, 1648–1659. [Google Scholar] [CrossRef] [PubMed]
- Moskowitz, C.H.; Walewski, J.; Nademanee, A.; Masszi, T.; Agura, E.; Holowiecki, J.; Abidi, M.H.; Chen, A.I.; Stiff, P.; Viviani, S.; et al. Five-year PFS from the AETHERA trial of brenduximab vedotin for Hodgkin lymphoma at risk of progression or relapse. Blood 2018, 123, 2639–2642. [Google Scholar] [CrossRef] [Green Version]
- Shibon, D.; Morschhauser, F.; Eche-Rigon, M.; Ghez, D.; Dupuis, J.; Marçais, A.; Deau-Fischer, B.; Bouabdallah, R.; Sebban, C.; Salles, G.; et al. Single or tandem autologous stem-cell transplantation for first -relapsed or refractory Hodgkin lymphoma: 10-years follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Hematologica 2016, 101, 474–481. [Google Scholar] [CrossRef] [Green Version]
- Smith, E.P.; Li, H.; Friedberg, J.W.; Constine, L.S.; Rimsza, L.M.; Cook, J.R.; Laport, G.G.; Popplewell, L.L.; Holmberg, L.A.; Smith, S.M.; et al. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant. 2018, 24, 700–707. [Google Scholar] [CrossRef] [Green Version]
- Younes, A.; Gopal, A.K.; Smith, S.E.; Ansell, S.M.; Rosenblatt, J.D.; Savage, K.J.; Ramchandren, R.; Bartlett, N.L.; Cheson, B.D.; de Vos, S.; et al. Results of a pivotal phase II study brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 2012, 30, 2183–2189. [Google Scholar] [CrossRef] [PubMed]
- Armand, P.; Engert, A.; Younes, A.; Fanale, M.; Santoro, A.; Zinzani, P.L.; Timmerman, J.M.; Collins, G.P.; Ramchandren, R.; Cohen, J.B.; et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase CheckMate 205 trial. J. Clin. Oncol. 2018, 36, 1428–1439. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Zinzani, P.L.; Lee, H.J.; Armand, P.; Johnson, N.A.; Brice, P.; Radford, J.; Ribrag, V.; Molin, D.; Vassilakopoulos, T.P.; et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow up of KEYNOTE-087. Blood 2019, 134, 1144–1153. [Google Scholar] [CrossRef] [Green Version]
- Martinez, C.; Canals, C.; Sarina, B.; Alessandrino, E.P.; Karakasis, D.; Pulsoni, A.; Sica, S.; Trneny, M.; Snowden, J.A.; Kanfer, E.; et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann. Oncol. 2013, 24, 2430–2434. [Google Scholar] [CrossRef]
- Appelbaum, F.R.; Sullivan, K.M.; Deeg, H.J.; Neiman, P.E.; Sanders, J.E.; Stewart, P.; Storb, R. Allogeneic bone marrow transplanatation in the treatment of MOPP-resistant Hodgkin’s disease. J. Clin. Oncol. 1985, 3, 1490–1494. [Google Scholar] [CrossRef]
- Phillips, G.L.; Reece, D.E.; Barnett, M.J.; Connors, J.M.; Fay, J.W.; Herzig, G.P.; Herzig, R.H.; Klingemann, H.G.; Shepherd, J.D.; Wolff, S.N. Allogeneic marrow transplanatation for refractory Hodgkin disease. J. Clin. Oncol. 1989, 7, 1039–1045. [Google Scholar] [CrossRef]
- Gajewski, J.L.; Philips, G.L.; Sobocinski, K.A.; Armitage, J.O.; Gale, R.P.; Champlin, R.E.; Herzig, R.H.; Hurd, D.D.; Jagannath, S.; Klein, J.P.; et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J. Clin. Oncol. 1996, 14, 572–578. [Google Scholar] [CrossRef] [PubMed]
- Milpied, N.; Fielding, A.K.; Perace, R.M.; Ernst, P.; Goldstone, A.H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J. Clin. Oncol. 1996, 14, 1291–1296. [Google Scholar] [CrossRef] [PubMed]
- Sureda, A.; Schmitz, N. Role of allogeneic stem cell transplantation in relapse or refractory Hodgkin’s disease. Ann. Oncol. 2002, 13 (Suppl. 1), 128–132. [Google Scholar] [CrossRef] [PubMed]
- Sureda, A.; Genadieva Stavrik, S.; Boumendil, A.; Finel, H.; Khvedelidze, I.; Dietricht, S.; Dreger, P.; Hermine, O.; Kyriakou, C.; Robinson, S.; et al. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: An analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transpl. 2020, 55, 2170–2179. [Google Scholar] [CrossRef] [PubMed]
- Sureda, A.; Robinson, S.; Canals, C.; Carella, A.M.; Boogaerts, M.A.; Caballero, D.; Hunter, A.E.; Kanz, L.; Slavin, S.; Cornelissen, J.J.; et al. Reduced-intensity conditioning compared with conventional allogeneic stem cell transplantation in relapsed or refractory Hodgkin’s lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 2008, 26, 455–462. [Google Scholar] [CrossRef]
- Robinson, S.P.; Sureda, A.; Canals, C.; Russell, N.; Caballero, D.; Bacigalupo, A.; Iriondo, A.; Cook, G.; Pettitt, A.; Socie, G.; et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: Identification of prognostic factors predicting outcome. Hematologica 2009, 94, 230–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Genadieva-Stavrik, S.; Boumendil, A.; Dreger, P.; Peggs, K.; Briones, J.; Corradini, P.; Bacigalupo, A.; Socié, G.; Bonifazi, F.; Finel, H.; et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: A retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann. Oncol. 2016, 27, 2251–2257. [Google Scholar] [CrossRef]
- Anderlini, P.; Saliba, R.; Acholonu, S.; Okoroji, G.J.; Donato, M.; Giralt, S.; Andersson, B.; Ueno, N.T.; Khouri, I.; De Lima, M.; et al. Reduced-intensity allogeneic stem cell transplantation in relapse and refractory Hodgkin’s disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005, 35, 943–951. [Google Scholar] [CrossRef] [Green Version]
- Alvares, I.; Sureda, A.; Caballero, M.D.; Urbano-Ispizua, A.; Ribera, J.M.; Canales, M.; García-Conde, J.; Sanz, G.; Arranz, R.; Bernal, M.T.; et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:result of a Spanish prospective cooperative protocol. Biol. Blood Marrow Transplant. 2006, 12, 172–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peggs, K.S.; Sureda, A.; Qian, W.; Caballero, D.; Hunter, A.; Urbano-Ispizua, A.; Cavet, J.; Ribera, J.M.; Parker, A.; Canales, M.; et al. Reduced intensity conditioning for allogeneic haematopoetic stem cell transplantation in relapsed and refractory Hodgkin lymphoma; impact of alemtuzumab and donor lymphocyte infusion on long term outcomes. Br. J. Hematol. 2007, 139, 70–80. [Google Scholar] [CrossRef]
- Das-Gupta, E.; Tomson, K.J.; Bloor, A.J.C.; Clark, A.D.; Mackinnon, S.; Kayani, I.; Clifton-Hadley, L.; Patrick, P.; El-Mehidi, N.; Lawrie, A.; et al. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: A single-arm, multicenter study. Blood Adv. 2019, 3, 4264–4270. [Google Scholar] [CrossRef] [Green Version]
- Peggs, K.S.; Kayani, I.; Edwards, N.; Kottaridis, P.; Goldstone, A.H.; Linch, D.C.; Hough, R.; Morris, E.C.; Fielding, A.; Chakraverty, R.; et al. Donor lymphocyte infusion modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J. Clin. Oncol. 2011, 29, 971–978. [Google Scholar] [CrossRef]
- Peggs, K.S.; Hunter, A.; Chopra, R.; Parker, A.; Mahendra, P.; Milligan, D.; Craddock, C.; Pettengell, R.; Dogan, A.; Thomson, K.J.; et al. Clinical evidence of a graft-versus Hodgkin’s lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005, 365, 1934–1941. [Google Scholar] [CrossRef]
- Bazarbachi, A.; Boumendil, A.; Finel, H.; Mohty, M.; Castagna, L.; Peggs, K.S.; Blaise, D.; Afanasyev, B.; Diez-Martin, J.L.; Sierra, J.; et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: A report from the EBMT Lymphoma Working Party. Br. J. Haematol. 2018, 181, 86–96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perrot, A.; Monjanel, H.; Bouabdallah, R.; Quittet, P.; Sarkozy, C.; Bernard, M.; Stamatoullas, A.; Borel, C.; Bouabdallah, K.; Nicolas-Virelizier, E.; et al. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: A large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica 2016, 101, 466–473, PMCID:PMC5004383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Merryman, R.W.; Castagna, L.; Giordano, L.; Ho, V.T.; Corradini, P.; Guidetti, A.; Casadei, B.; Bond, D.A.; Jaglowski, S.; Spinner, M.A.; et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 2021, 35, 2672–2683. [Google Scholar] [CrossRef] [PubMed]
- Castagna, L.; Bramanti, S.; Devillier, R.; Sarina, B.; Crocchiolo, R.; Furst, S.; El-Cheikh, J.; Granata, A.; Faucher, C.; Harbi, S.; et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transpl. 2017, 52, 683–688. [Google Scholar] [CrossRef] [PubMed]
- Mariotti, J.; Bramanti, S.; Santoro, A.; Castagna, L. Haploidentical stem cell Transplantation in lymphomas-expectation and ptifals. J. Clin. Med. 2020, 9, 3589–3605. [Google Scholar] [CrossRef]
- Marani, C.; Raiola, A.M.; Morbelli, S.; Dominietto, A.; Ferrarazzo, G.; Avenoso, D.; Giannoni, L.; Varaldo, R.; Gualandi, F.; Grazia, D.; et al. Haploidentical transplant with post-transplant cyclophosphamide for relapsed or refractory Hodgkin lymphoma: The role of comorbidity index and pretransplant positron emission tomography. Biol. Blood Marrow Transpl. 2018, 24, 2501–2508. [Google Scholar] [CrossRef] [Green Version]
- Kanate, A.S.; Mussetti, A.; Kharfan-Dabaja, M.A.; Ahn, K.W.; DiGilio, A.; Beitinjaneh, A.; Chhabra, S.; Fenske, T.S.; Freytes, C.; Gale, R.P.; et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs. HLA-mached unrelated donors. Blood 2016, 127, 938–947. [Google Scholar] [CrossRef]
- Ghosh, N.; Karmali, R.; Rocha, V.; Ahn, K.W.; DiGilio, A.; Hari, P.N.; Bachanova, V.; Bacher, U.; Dahi, P.; de Lima, M.; et al. Reduced-intensity transplantation for lymphomas using haploidentical realated donors versus hla-matched sibling donors: A center for International Blood and Marrow transplant Research Analysis. J. Clin. Oncol. 2016, 34, 3141–3149. [Google Scholar] [CrossRef]
- Burroughs, L.M.; O’Donnell, P.V.; Sandmaier, B.M.; Storer, B.E.; Luznik, L.; Symons, H.J.; Jones, R.J.; Ambinder, R.F.; Maris, M.B.; Blume, K.G.; et al. Comparison of outcome of HLA-matched related, unrelated or HLA-haploidentical related hematopoetic ceklkl transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol. Blood Marrow Transpl. 2008, 14, 1279–1287. [Google Scholar] [CrossRef] [Green Version]
- Gayoso, J.; Balsalobre, P.; Pascual, M.J.; Castilla-Llorente, C.; López-Corral, L.; Kwon, M.; Serrano, D.; Piñana, J.L.; Herrera, P.; Ferrá, C.; et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma:Spanish multicenter experience. Bone Marrow Transpl. 2016, 51, 1307–1312. [Google Scholar] [CrossRef] [Green Version]
- Martinez, C.; Gayoso, J.; Canals, C.; Finel, H.; Peggs, K.; Dominietto, A.; Castagna, L.; Afanasyev, B.; Robinson, S.; Blaise, D.; et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: A registry study of the lymphoma working party of the European Society for Blood and marrow transplantation. J. Clin. Oncol. 2017, 35, 3425–3432. [Google Scholar] [PubMed] [Green Version]
- Dietrich, S.; Dreger, P.; Hermine, O.; Kyriakou, C.; Montoto, S.; Robinson, S.; Schmitz, N.; Schouten, H.C.; Sureda, A.; Tanase, A. Haploidentical stem cell transplantation for patients with lymphoma: A position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2020, 55, 317–324. [Google Scholar] [CrossRef]
- Bazarbachi, A.; Boumendil, A.; Finel, H.; Castagna, L.; Dominietto, A.; Blaise, D.; Diez-Martin, J.L.; Tischer, J.; Gülbas, Z.; Wallet, H.L.; et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma—A LWP-EBMT study. Br. J. Haematol. 2020, 188, 745–756. [Google Scholar] [CrossRef] [PubMed]
- Mariotti, J.; Devillier, R.; Bramanti, S.; Giordano, L.; Sarina, B.; Furst, S.; Granata, A.; Maisano, V.; Pagliardini, T.; De Philippis, C.; et al. peripheral blood stem cell versus Bone Marrow for the T-cell deplete haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin lymphoma. Biol. Blood Marrow Transpl. 2019, 25, 1810–1817. [Google Scholar] [CrossRef] [PubMed]
- Mariotti, J.; Raiola, A.M.; Evangelista, A.; Carella, A.M.; Martino, M.; Patriarca, F.; Risitano, A.; Bramanti, S.; Busca, A.; Giaccone, L.; et al. Impact of donor age and kinship on clinical outcome after T-cell -replete haploidentical transplantation with PT-Cy. Blood Adv. 2020, 4, 3900–3912. [Google Scholar] [CrossRef] [PubMed]
- Castagna, L.; Busca, A.; Bramanti, S.; Raiola Anna, M.; Malagola, M.; Ciceri, F.; Arcese, W.; Vallisa, D.; Patriarca, F.; Specchia, G.; et al. Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. BMC Cancer 2020, 20, 1140, PMCID:PMC7685618. [Google Scholar] [CrossRef] [PubMed]
- Bazarbachi, A.; Boumendil, A.; Finel, H.; Mohty, M.; Castagna, L.; Blaise, D.; Peggs, K.S.; Afanasyev, B.; Diez-Martin, J.L.; Corradini, P.; et al. Brentuximab Vedotin for Recurrent Hodgkin Lymphoma After Allogeneic Hematopoetic Stem cell Transplantation: A Report from the EBMT Lymphoma Working Party. Cancer 2019, 125, 90–98. [Google Scholar] [CrossRef]
- Gopal, A.K.; Ramchandren, R.; O’Conor, O.A.; Berryman, R.B.; Advani, R.H.; Chen, R.; Smith, S.E.; Cooper, M.; Rothe, A.; Matous, J.V.; et al. Safety and efficacay of brenduximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplanatation. Blood 2012, 120, 560–568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herbaux, C.; Gauthier, J.; Brice, P.; Drumez, E.; Ysebaert, L.; Doyen, H.; Fornecker, L.; Bouabdallah, K.; Manson, G.; Ghesquières, H.; et al. Efficacy and tolerability of nivolumab after allogeneic transplanatation for relapsed Hodgkin lymphoma. Blood 2017, 129, 2471–2478. [Google Scholar] [CrossRef] [Green Version]
- Ansell, S.M.; Lesokhin, A.M.; Borrelo, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; et al. PD-1 blocade with nivolumab in relapsed or refractory Hodgkin lymphoma. N. Engl. J. Med. 2015, 372, 311–319. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Armand, P.; Shipp, M.A.; Ribarg, V.; Michot, J.M.; Zinzani, P.L.; Kuruvilla, J.; Snyder, E.S.; Ricart, A.D.; Balakumaran, A.; Rose, S.; et al. Programmed death-1 blocade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J. Clin. Oncol. 2016, 34, 3733–3739. [Google Scholar] [CrossRef]
- Passweg, J.R.; Baldomero, H.; Chabannon, C.; Basak, G.W.; de la Cámara, R.; Corbacioglu, S.; Dolstra, H.; Duarte, R.; Glass, B.; Greco, R.; et al. European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: Monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021. [Google Scholar] [CrossRef] [PubMed]
- Ramos, C.A.; Grover, N.S.; Beaven, A.W.; Lulla, P.D.; Wu, M.F.; Ivanova, A.; Wang, T.; Shea, T.C.; Rooney, C.M.; Dittus, C.; et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin Lymphoma. J. Clin. Oncol. 2020, 38, 3794–3804. [Google Scholar] [CrossRef]
- Bartlett, N.L.; Herrera, A.F.; Domingo-Domenech, E.; Mehta, A.; Forero-Torres, A.; Garcia-Sanz, R.; Armand, P.; Devata, S.; Izquierdo, A.R.; Lossos, I.S.; et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2020, 136, 2401–2409, PMCID:PMC7685206. [Google Scholar] [CrossRef] [PubMed]
- Badar, T.; Astle, J.; Kakar, I.K.; Zellner, K.; Hari, P.N.; Hamadani, M. Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. Br. J. Haematol. 2020, 190, e98–e101. [Google Scholar] [CrossRef] [PubMed]
Authors | Pts (n) | Study Arms | OS | PFS | NRM | Stem-Cell Source |
---|---|---|---|---|---|---|
Linch, 1993 [13] | 40 | BEAM vs. Mini-BEAM | 78% vs. 60% | 53% vs. 10% | 10% vs. 0 | BM |
Schmitz, 2002 [14] | 144 | BEAM vs. Dexa BEAM | 71% vs. 65% | 55% vs. 34% | 6 vs. 6 pts | PBSC |
Primary Ref. | CR-PET-CT Neg Pre Auto-HCT | CD 34 + Cells/kg Collected ×106 | Auto-HCT | PFS ITT | ORR | |
---|---|---|---|---|---|---|
BeGV [17] | 32 | 73 | 8.8 | 73 | 63% at 2 y | 83 |
ICE [18] | 20 | 26 | 7 | 85 | 58% at 2 y | 88 |
DHAP [19] | 16 | 21 | 6.1 | NA | NA | 89 |
GVD [20] | NA | 20 | NA | 76 | 52% at 4 y | 70 |
N | Rel | Primary Ref | CR-PET-CT Neg Pre Auto-HCT | CD 34 + Cells/kg Collected ×106 | Auto-HCT | PFS ITT | ORR | |
---|---|---|---|---|---|---|---|---|
BV sequential ICE [21] | 66 | 33 | 33 | 73 | 6.2 | 95 | 79% at 3 years | 77 |
BV—sequential salvage therapy [22] | 37 | 13 | 24 | 73 | 5.6 | 89 | 72% at 1.5 years | 50 |
BV-ESHAP [23] | 66 | 26 | 40 | 80 | 5.75 | 92 | NA | 70 |
Benda-BV [24] | 55 | 27 | 27 | 74 | 4 | 74 | 63% at 2 years | 74 |
BV-ICE [25] | 16 | 5 | 11 | 69 | 11 | 75 | NA | 69 |
BV-DHAP [26] | 12 | 10 | 2 | 90 | 5.3 | 100 | NA | 90 |
BV-Nivo [27] | 62 | 34 | 28 | 64 | 4.7 | 54 | NA | 62 |
Reference | Transplant Period | No. of Transplant Recipients and Conditioning Regimen | Prior Auto HCT | OS | PFS | Response to Immunotherapy with DLI |
---|---|---|---|---|---|---|
Robinson et al. [45] | 1995–2005 | RIC-285 | 80% | 29%/3 y | 25% | 41/79 (52%) |
Anderlini et al. [47] | 2001–2005 | RIC-58 FluCy ± ATG/FluMel | 48 (83%) | 64%/2 y | 32% | 6/14 (43%) |
Alvarez et al. [48] | 1999–2004 | RIC-40 FluMel | 29 (73%) | 48%/2 y | 32% | 6/11 (55%) |
Peggs et al. [49] | 1997–2003 | RIC-49 FluMelAlemtuzumab FluMel | 44 (90%) | 73%/2 y | 39% | 13/19 (68%) (FluMel-Alemtuzumab) 6/11. (55%) (FluMel) |
Sureda et al. [44] | 1997–2001 | 168 RIC-89 MAC-79 | RIC-55 (61.8%) MAC-32 (40.5%) | 28% 22% | 18% 20% | NS |
Genadieva-Stavrikj et al. [46] | 2006–2010 | 312 RIC-249 MAC-63 | RIC-155 (62%) MAC-17 (27%) | 62%/2 y 73%/2 y | 36% 48% | NS |
Number of Patients | Conditioning | Type of Graft BM/PBSC% | Disease Status SD/PD% | Prior Auto HCT% | aGVHD | cGVHD | OS | PFS | NRM | RI | |
---|---|---|---|---|---|---|---|---|---|---|---|
Burroughs 2008 [61] | 90 | NMA | 100 | 43 | 89 | 43 | 35/2 y | 2 y/58 | 2 y/51 | 2 y/9 | 2 y/40 |
Kanate 2016 [59] | 46 | NMA | 93/7 | 5 | 72 | 27 | 13/1 y | 3 y/60 | 3 y/47 | 3 y/17 | 3 y/37 |
Ghosh 2016 [60] | 44 | NMA/RIC | 93/7 | 6 | 38 | 27 | 15/1 y | 3 y/37 | 3 y/48 | 3 y/15 | 3 y/37 |
Gayoso 2016 [62] | 43 | RIC | 28/72 | NA | 79 | 39 | 19/2 y | 2 y/58 | 2 y/48 | 1 y/21 | 2 y/24 |
Martinez 2017 [63] | 98 | RIC/NMA | 61/39 | 15 | 77 | 33 | 26/1 y | 2 y/67 | 2 y/43 | 1 y/17 | 2 y/39 |
Castagna 2017 [56] | 62 | NMA/RIC | 63/37 | 13 | 40 | 23 | 16/167 d | 3 y/63 | 3 y/59 | 1 y/20 | 3 y/21 |
Marani 2018 [58] | 41 | NMA | 100 | 68 | 100 | 21 | 12 | 3 y/76 | 3 y/44 | 3 y/7.5 | 3 y/55 |
Reference | Previous Treatment R/R after HCT | N | Treatment | ORR | CR | Median for CR Patients |
---|---|---|---|---|---|---|
Younes A 2012 [32] | After auto-HCT | 102 | Brentuximab vedotin | 75% | 34% | 20.5 |
Armand P 2018. [33] | After auto-HCT and BV | 243 | Nivolumab | 69% | 16% | 22.2 |
Chen R 2019. [34] | After autoHCT, BV | 210 | Pembrolizumab | 71.9% | 27,6 | NR |
Ramos CA 2020 [75] | After BV, Nivo, auto/allo HCT | 41 | antiCD30CAR-T cell | 72% | 59% | 41%/1 y |
Gopal AK 2012. [70] | After allo-HCT | 25 | Brentuximab vedotin | 50% | 38% | |
Herbaux C 2017. [71] | After allo-HCT | 20 | Nivolumab | 95% | 42% including PR | 58.2/1 y |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Stavrik, S.G.; Sureda, A. Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma. Transplantology 2021, 2, 396-411. https://doi.org/10.3390/transplantology2040038
Stavrik SG, Sureda A. Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma. Transplantology. 2021; 2(4):396-411. https://doi.org/10.3390/transplantology2040038
Chicago/Turabian StyleStavrik, Sonja Genadieva, and Anna Sureda. 2021. "Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma" Transplantology 2, no. 4: 396-411. https://doi.org/10.3390/transplantology2040038